Abstract
Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.
| Original language | English |
|---|---|
| Pages (from-to) | 1291-1304 |
| Number of pages | 14 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 7 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jul 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Pharmacoeconomic considerations with statin therapy. / Speidel, Katie M.; Hilleman, Daniel E.
In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 10, 07.2006, p. 1291-1304.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacoeconomic considerations with statin therapy
AU - Speidel, Katie M.
AU - Hilleman, Daniel E.
PY - 2006/7
Y1 - 2006/7
N2 - Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.
AB - Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.
UR - http://www.scopus.com/inward/record.url?scp=34447098428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447098428&partnerID=8YFLogxK
U2 - 10.1517/14656566.7.10.1291
DO - 10.1517/14656566.7.10.1291
M3 - Review article
C2 - 16805716
AN - SCOPUS:34447098428
VL - 7
SP - 1291
EP - 1304
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 10
ER -